Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AVAX Technologies, Inc.
AVAX Presents Results of a Dose-Response Study of MVax at American Society of Clinical Oncology ASCO
June 18th, 2008
AVAX Technologies, Inc. (OTC Market: AVXT.OB) presented the results of its phase I-II trial of MVax(R), its autologous, hapten-modified melanoma vaccine, at the annual meeting of the American Society for Clinical Oncology (ASCO) at a poster session held Sunday, June 1. The presentation, entitled, "Dose-response study of a cryopreserved, autologous, hapten-modified melanoma vaccine (MVax(R))," analyzed the safety and immunological efficacy of MVax in 82 patients with Stage III or IV metastatic melanoma. Patients were blindly assigned to one of four dosage groups: 5 million, 2.5 million, 0.5 million or zero (control arm) melanoma cells per dose. In all groups MVax was...
Source: Vaccine Weekly (2008-06-18)
|
